Biocon Q2 Results: Profit soars 428% YoY to Rs 85 crore on strong biosimilar and generics growth
Biocon Group on Tuesday reported a 20% year-on-year increase in operating revenue in the second quarter of FY26 to Rs 4,296 crore, driven by robust growth in biosimilars, improved momentum in generics, and a steady contribution from the CRDMO segment. EBITDA grew 29% to Rs 928 crore, while net profit for the period stood at…